Financial Data and Key Metrics Changes - The company achieved a 35% year-over-year reduction in pro forma operating expenses, reflecting improved efficiency and focus on portfolio optimization [14][48]. - Cash operating expenses for 2026 are expected to be under $390 million, with a cash balance of $754 million at the end of the previous year, extending the cash runway to early 2028 [48][50]. Business Line Data and Key Metrics Changes - The company reported significant progress in its clinical development, including a positive proof of concept for FAP and multiple milestones achieved with Sanofi, indicating a diversified and advancing clinical portfolio [8][36]. - The AI-enabled chemistry platform has shown to synthesize 90% fewer compounds than industry standards, achieving faster development timelines, with an average of 17 months compared to the industry average of over 42 months [13][43]. Market Data and Key Metrics Changes - The company has generated over $500 million in cumulative cash inflows from partnerships, with potential for over $300 million in milestones per small molecule program, indicating strong market validation and economic potential [35][36]. - The collaboration with Sanofi has advanced five lead packages, contributing to $134 million in milestones to date, showcasing the strength of partnerships in driving market success [36][37]. Company Strategy and Development Direction - The company is focused on three strategic pillars: tangible proof points in clinical and partner programs, surgical investment in its platform, and disciplined execution to maximize impact [10][11]. - The integration of AI across the entire R&D lifecycle is a core strategy, aiming to unlock value through better targets, molecules, and faster program advancements [3][10]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the broader momentum in the biotech sector, emphasizing the importance of translating AI capabilities into real-world applications and measurable impacts [2][3]. - The company is on track for initial engagement with the FDA regarding REC-4881 and anticipates a busy 18-24 months with multiple catalysts expected [51][55]. Other Important Information - The company has built over 50 petabytes of high-quality multimodal data, which is crucial for developing state-of-the-art foundation models in biology and chemistry [40][41]. - The integration of a newly built clinical development AI platform is expected to improve enrollment rates and operational efficiency significantly [44][45]. Q&A Session Summary Question: What potential registrational pathway may look like for REC-4881? - The company is on track for initial engagement with the FDA in the first half of 2026 to discuss the registrational study design and patient population [54][55]. Question: Are there any one-offs that helped in Q4 regarding cost optimization? - The focus has been on efficiency rather than one-off cost cuts, with expectations to continue finding ways to do more with less [56][57]. Question: What is the rationale behind the divestment from NVIDIA? - The divestment is part of NVIDIA's shift in investment strategy, while the technical collaboration with NVIDIA continues to strengthen [60][61].